MK1026-003: A phase 2 trial of the medication MK-1026 in blood cancers

This trial is looking at the safety and effectiveness of the medication MK-1026 in blood cancers including lymphoma.

You can share the following CRUK.org Identifier with your medical team so they can find out more about the trial: CRUK18341

Trial aim and background  

MK-1026 is a type of cancer drug called a bruton tyrosine kinase inhibitor (BTKi) which stops the signals cancer cells use to divide and grow. This trial is aiming to see how well it works in people with blood cancers including lymphoma that has not responded to treatment (refractory), or has come back after treatment (relapsed). It also aims to establish the optimal dose, the safety, how it affects the body and the impact it has on quality of life.

The trial is in two parts:

  1. The dose escalation phase which aims to determine the best dose of MK-1026 to use.
  2. Testing this dose in 8 groups of participants which are determined by cancer type.

Everyone in the trial receives MK-1026, some will be asked to have further bone marrow biopsies or lymph node tissue sample. Everyone will have to fill out a quality of life questionnaire.

Who can enter

To join the first part of the trial people must have chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).

To join the second part people must have CLL, SLL, mantle cell lymphoma, marginal cell lymphoma, follicular lymphoma, Waldenstrom’s macroglobulinaemia or Richter’s transformation.

All participants must have relapsed or refractory disease.

Locations

Recruitment is taking place in the following UK locations:

  • Bristol
  • Cambridge
  • London
  • Manchester
  • Nottingham
  • Oxford
  • Sutton 
  • Windsor

Further information 

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-of-mk-1026-for-some-types-of-blood-cancer-mk1026-003

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.